Recent trends in the treatment of unresectable stage III non-small-cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine
Reference43 articles.
1. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501;Nogami;Lung Canc,2015
2. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801;Aoe;Eur J Cancer,2014
3. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer;Kuyama;J Thorac Oncol,2008
4. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007;Segawa;J Clin Oncol,2010
5. Kiura K Cure- or care-oriented regimen for stage III non-small-cell lung cancer?;Hotta;J Clin Oncol,2011
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Short-term and long-term outcomes of induction chemoimmunotherapy before radical thoracic radiotherapy or chemoradiotherapy for unresectable stage III non-small cell lung cancer;2023-06-09
2. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial;Signal Transduction and Targeted Therapy;2023-02-24
3. Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel;Pulmonology;2023-01
4. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival;Translational Lung Cancer Research;2021-01
5. Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K/AKT pathway in lung adenocarcinoma;Surgical Oncology;2020-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3